Scientific Name: Adagrasib
Brand Name: Krazati
Company Owner: Not Available
Mechanism Of Action In normal cells, KRAS is activated by binding to guanosine triphosphate (GTP) , and this promotes the activation of the MAP kinase pathway and intracellular signal transduction. When GTP is hydrolyzed to guanosine diphosphate (GDP) , KRAS is inactivated. This mechanism works as an “on”/”off” system that regulates cell growth. The substitution of Gly12 by cysteine in KRAS (KRAS
Description of the Drug: Adagrasib is a KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy.
Protein Data Bank: Not Available
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB15568